Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

741
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
741
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

1.1K
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Getting home in the dark.

Science (New York, N.Y.)·2026
Same author

Impact of oral iron dosing regimens on iron biomarkers during pregnancy: insights from the PANDA trial.

Blood advances·2026
Same author

Characterization of ferroportin disease and SLC40A1-related hemochromatosis - Results from the EASL non-HFE registry.

Journal of hepatology·2026
Same author

Iron-Rim Lesions in the Optic Chiasm in Multiple Sclerosis: A Neuropathologic Case Series.

Neurology·2026
Same author

Topographical Variation of Iron-Rimmed Lesions in the Multiple Sclerosis Brain and Spinal Cord: A Neuropathological Study.

Annals of neurology·2026
Same author

Iron-sepsis associations in population health revealed by epidemiology.

EBioMedicine·2025

Related Experiment Video

Updated: Mar 27, 2026

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay
05:08

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay

Published on: January 31, 2022

5.7K

Next-Generation Biomarkers for Iron Status.

Hal Drakesmith

    Nestle Nutrition Institute Workshop Series
    |January 15, 2016
    PubMed
    Summary

    Hepcidin, a key hormone regulating iron absorption, is crucial for treating iron deficiency anemia. Understanding hepcidin levels helps guide effective iron therapy and manage complex anemias.

    Area of Science:

    • Biochemistry
    • Hematology
    • Physiology

    Background:

    • Iron is essential for vital physiological processes, including oxygen transport and DNA synthesis.
    • Hepcidin, a peptide hormone, is the primary regulator of iron absorption and distribution.
    • Iron deficiency anemia is common, but other conditions like inflammation and inherited disorders can cause anemia and iron dysregulation.

    Purpose of the Study:

    • To highlight the role of hepcidin in iron homeostasis and its regulation.
    • To discuss the challenges in assessing iron status and diagnosing iron deficiency anemia.
    • To explore the potential of hepcidin as a biomarker for guiding iron treatment and managing related conditions.

    Main Methods:

    • Review of existing literature on iron metabolism and hepcidin.

    More Related Videos

    Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism
    05:36

    Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism

    Published on: February 23, 2024

    1.0K
    Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
    08:45

    Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

    Published on: May 10, 2022

    2.6K

    Related Experiment Videos

    Last Updated: Mar 27, 2026

    Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay
    05:08

    Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay

    Published on: January 31, 2022

    5.7K
    Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism
    05:36

    Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism

    Published on: February 23, 2024

    1.0K
    Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
    08:45

    Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

    Published on: May 10, 2022

    2.6K
  • Analysis of diagnostic challenges and limitations of current iron status biomarkers.
  • Discussion of hepcidin's role in various clinical contexts, including anemia and transplantation.

    • Main Results:

    • Hepcidin levels are influenced by iron stores, inflammation, and erythropoiesis.
    • Current iron status biomarkers have limitations, complicating diagnosis and treatment.
    • Low hepcidin levels facilitate iron absorption and red blood cell incorporation.

    Conclusions:

    • Hepcidin is a critical determinant of iron utilization and a potential biomarker for guiding iron therapy.
    • Effective management of iron status, particularly in anemia, may benefit from hepcidin assessment.
    • Hepcidin's role extends to transplantation medicine and managing conditions like pulmonary hypertension.